Increasing physical activity in older adults has important implications for treating obesity related metabolic conditions, however the interaction of aging- and obesity-related declines in physical function may make adding structured exercise particularly challenging for this group. Given these challenges, an alternative prescription to traditional structured exercise, may be short bouts of intermittent walking scattered throughout the day - this may be an effective strategy to increase physical activity, reduce sedentary behavior, and improve glycemic control in overweight/obese older adults. The purpose of this project is to determine how interrupting sedentary time with short bouts of moderate intensity walking affects important metabolic outcomes in older, overweight adults. It would also be of interest to compare the effects of short, frequent interruptions in sedentary behavior to a traditional exercise prescription (continuous 30 min walking bout) on metabolic outcomes (e.g., glycemic control, insulin sensitivity, and 24 h fat oxidation). Thus, the overall aims of the proposed research are to 1) Determine the effect of performing short bouts of moderate-intensity intermittent walking (IW) on glucose and insulin metabolism compared to uninterrupted sitting (US) in older overweight and obese adults. 2) To compare the effects of interrupting sedentary time (IW) vs. a traditional exercise prescription (continuous 30 m walk (CW)) on metabolism.

The investigators hypothesize that interrupting sedentary time with intermittent walking will improve glucose and insulin metabolism compared to uninterrupted sitting and it will be as effective at improving metabolism as a single continuous 30 min walk.

Inclusion Criteria:

• Aged 60-85 yr • BMI 25-35 kg.m-2
• Non-exercisers (<150 m/wk of moderate intensity exercise)
• Sedentary (>60% of waking day sedentary)
• Able to walk on a treadmill for 36 continuous minutes at a pace of at least 2.0 mph

Exclusion Criteria:

• Self-reported acute or chronic disease (e.g. diabetes, heart disease, thyroid disease)
• Fasting plasma glucose ≥ 126 mg/dl - participants will not be excluded if they an abnormal post prandial glucose levels (e.g. glucose ≥ 200 mg/dl) following the MTT's.
• Tobacco use (cigarettes, cigars, or chewing tobacco) within the past 6 months
• Females who previously used (> 6 months) or are currently using any formulation of estrogen-based hormone therapy (e.g., oral Premarin, transdermal 17-estradiol, selective estrogen receptor modulators).
• Resting diastolic blood pressure > 100 mm mercury or resting systolic blood pressure > 160 mm mercury
• Contra-indications to exercise (e.g. orthopedic limitations)
• Unable to walk on a treadmill for 36 continuous minutes at a pace of at least 2.0 mph